

EAHP has a long-standing collaboration with the European Medicines Agency (EMA) and is involved in a wide range of activities:

Roberto Frontini member of PRAC



Dr Roberto Frontini, former Director of Pharmacy at the University Hospital of Leipzig in Germany and EAHP President from 2009 to 2015, is a member of the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) to represent healthcare professionals.

After serving for three years (mid-June 2019 until the end of February 2022) as an alternate member representing healthcare professionals on EMA's PRAC, Dr Roberto Frontini was appointed as a member representing healthcare professionals nominated by the European Commission in May 2022 for a three years period.

During the next mandate, Dr Frontini will be continuing to be the link between the PRAC and hospital pharmacy practice in particular when it comes to input from healthcare professionals for the practical implementation of advice included in the SmPC and risk management plans.

PRAC ^[1] is EMA's committee responsible for assessing and monitoring the safety of human medicines.

Find out more about the PRAC and its role HERE ^[2]

EAHP's membership in the Healthcare Professionals' Working Party (HCPWP) ^[3]



EMA established the HCPWP to further involve this group of stakeholders in its range of activities. The role of the HCPWP is to provide recommendations to the Agency on all matters of interest to healthcare professionals in relation to medicines. EAHP has joined the HCPWP in 2013, when it was created. As an active member, EAHP has provided recommendations to the EMA and its human scientific committees on all matters of interest in relation to medicines such as for example medicines shortages and vaccines.

EAHP is represented in the HCPWP ^[3] by Piera Polidori, Despoina Makridaki (both Board Directors of Professional Development) and Stephanie Kohl (Policy & Advocacy Officer).

EMA consultations and participation in workshops

EMA consultations are of great interest to EAHP members. Consequently, EAHP regularly participates in both the public and the expert consultations of the agency.

Last update: 1 September 2022

Links

[1] <https://www.ema.europa.eu/en/glossary/pharmacovigilance-risk-assessment-committee> [2]

<https://www.ema.europa.eu/en/committees/pharmacovigilance-risk-assessment-committee-prac> [3]

<https://www.ema.europa.eu/en/committees/working-parties-other-groups/chmp/healthcare-professionals-working-party>